The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey
dc.authorid | alan, ozkan/0000-0002-6635-2012 | |
dc.authorid | Cicin, Irfan/0000-0002-7584-3868 | |
dc.authorid | Eralp, Yesim/0000-0001-9603-4755 | |
dc.authorid | Kilickap, Saadettin/0000-0003-1637-7390 | |
dc.authorid | Uysal, Mukremin/0000-0002-8524-0665 | |
dc.authorid | bilgin, burak/0000-0003-1717-8246 | |
dc.authorwosid | alan, ozkan/AAV-5044-2020 | |
dc.authorwosid | Cicin, Irfan/AAQ-5575-2020 | |
dc.authorwosid | Eralp, Yesim/AAD-7194-2020 | |
dc.authorwosid | Demirkazık, Ahmet/AAG-7699-2020 | |
dc.authorwosid | Tatlı, Ali Murat/D-9111-2018 | |
dc.authorwosid | Kilickap, Saadettin/AAP-3732-2021 | |
dc.authorwosid | Uysal, Mukremin/B-8956-2014 | |
dc.contributor.author | Kilickap, S. | |
dc.contributor.author | Olmez, O. F. | |
dc.contributor.author | Cicin, I. | |
dc.contributor.author | Demirci, U. | |
dc.contributor.author | Alan, O. | |
dc.contributor.author | Cabuk, D. | |
dc.contributor.author | Sakalar, T. | |
dc.date.accessioned | 2024-06-12T11:24:06Z | |
dc.date.available | 2024-06-12T11:24:06Z | |
dc.date.issued | 2018 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description | 43rd ESMO Congress (ESMO) -- OCT 19-23, 2018 -- Munich, GERMANY | en_US |
dc.description.abstract | [Abstract Not Available] | en_US |
dc.description.sponsorship | European Soc Med Oncol,Japanese Soc Med Oncol | en_US |
dc.identifier.endpage | 505 | en_US |
dc.identifier.issn | 0923-7534 | |
dc.identifier.issn | 1569-8041 | |
dc.identifier.startpage | 505 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/26807 | |
dc.identifier.volume | 29 | en_US |
dc.identifier.wos | WOS:000459277303171 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.language.iso | en | en_US |
dc.publisher | Oxford Univ Press | en_US |
dc.relation.ispartof | Annals Of Oncology | en_US |
dc.relation.publicationcategory | Konferans Öğesi - Uluslararası - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | [No Keywords] | en_US |
dc.title | The efficacy and safety of crizotinib in patients with ROS1 positive advanced stage NSCLC: The real-world experience from Turkey | en_US |
dc.type | Conference Object | en_US |